SPRUCE BIOSCIENCES, INC. 8-K

What Happened
Spruce Biosciences, Inc. announced financial results for the quarter ended March 31, 2026 via a press release issued May 13, 2026 (furnished as Exhibit 99.1 to the Form 8-K). The company reported a preliminary, unaudited estimate of cash and cash equivalents of $107.3 million as of April 30, 2026. The company noted this estimate is preliminary, not audited, subject to change upon completion of closing procedures, and should not substitute for its formal SEC-filed financial statements.

Key Details

• Press release announcing Q1 2026 results issued May 13, 2026 and furnished as Exhibit 99.1 to the Form 8-K.
• Quarter covered: quarter ended March 31, 2026.
• Preliminary cash and cash equivalents: $107.3 million as of April 30, 2026 (unaudited; subject to change).
• Company stated it has no obligation to update the preliminary cash estimate; Exhibit 99.1 is furnished, not “filed” for certain SEC incorporation purposes.

Why It Matters
Cash balance and liquidity are key for biotech companies funding development programs. The $107.3M preliminary cash estimate gives investors a snapshot of Spruce’s short-term liquidity, but because the figure is unaudited and preliminary, investors should review the full press release and await the company’s formal SEC financial filings for complete, audited results and additional financial details.